Click here to download the MultiV research packet in Adobe Acrobat format.

A clinical trial was performed on the patented enzyme system CARBOGEN from Triarco Industries, Inc. at the University of Dayton Human Performance Lab, Dayton, OH by Janine T. Baer, Ph.D., RD, Associate Professor of Health and Sport Science. The purpose of the study was to investigate the effect of 160 mg of Carbogen® consumed with a meal replacement bar on exercise performance during 60 min of high intensity cycling.

After an overnight 12-hr fast 5 trained, male cyclists (mean VO2 max 70 ml/kg/min) performed two 60-min cycling bouts at 80% VO2 max followed by a sprint at 100% VO2 max. Subjects consumed a meal replacement bar plus either 160 mg Carbogen ? or 160 mg placebo 1 hour prior to each cycling bout. Blood glucose and lactate were determined at: fasting, 1 hr-post feeding, at 30 and 60 minutes of exercise and post-sprint. Glucose levels were consistently higher when Carbogen® was used, with the values after 60-min of exercise significantly higher than the placebo (Carbogen® 73.8+3.6 mg/dl vs. placebo 58.4+ 11.9mg/dl, P<.05) (Graph 1). Lactate values were also consistently lower with the values after 30 min of exercise significantly lower than the placebo (Carbogen® 1.2 + .05 vs. placebo 3.3+0.23, P<.05) (Graph 2). Subjects were able to maintain a 100% VO2 max workload significantly longer with Carbogen® vs. placebo (6.3+3.4 min vs.4.4+ 2.9 min, p<0.001) (Graph 3).Additionally, subjects reported a lower rate of perceived exertion during the exercise trial with Carbogen® (mean RPE 12 + 1.0) vs. placebo (mean RPE 13 + 1.0).